ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality

The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality.

ISCHEMIA: La anatomía y no la función es la que marca el pronóstico

Now, this new analysis suggests that anatomic severity can predict events. However (surprisingly, once more), altering this severity through angioplasty does not change the prognosis for hard points such as death or infarction (referring to 4 years of follow-up).

Perhaps only the subgroup with greater anatomical severity somewhat benefits from angioplasty in terms of a reduction in death and infarction rates.

A total of 5179 patients with moderate to severe ischemia were randomized to an initial invasive strategy vs. a conservative strategy. An independent, blinded laboratory interpreted the extent and severity of coronary artery disease on computerized tomography (CT).

When comparing patients with no ischemia or mild ischemia vs. those with moderate or severe ischemia, no mortality increase was observed among the latter (moderate ischemia hazard ratio [HR]: 0.89; 95% confidence interval [CI]: 0.61 to 1.30; severe ischemia HR: 0.83; 95% CI: 0.57 to 1.21; p = 0.33).

The rate of non-fatal infarction increased with ischemia severity, although this is only a trend that becomes non-significant when adjusting for all variables.


Read also: Device Evolution Also Impacts on Valve in Valve.


This is very different from what was observed with the burden of coronary disease, given that, when comparing the extremes (no disease or mild disease vs. moderate or severe disease) there was almost a 3-fold increase in mortality (HR: 2.72; 95% CI: 1.06 to 6.98), and an almost 4-fold increase in infarction (HR: 3.78; 95% CI: 1.63 to 8.78).

The ischemic burden was not an indicator to select patients who might benefit from revascularization. In contrast, those with more severe anatomic disease (n = 659) who underwent revascularization showed a decrease in cardiovascular death and infarction at 4 years of follow-up (a difference of 6.3%; CI 95%: 0.2% to 12.4%). The difference only affected cardiovascular death, since all-cause death rates were similar.

Conclusion

Ischemia severity was not associated with increased risk, in contrast to what occurred with anatomy, where greater disease severity did translate into increased risk.

The initial invasive strategy did not decrease events across the spectrum of ischemic burden severity after 4 years of follow-up.

CIRCULATIONAHA-120-049755

Original Title: Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity.

Reference: Harmony R. Reynolds et al. Circulation. 2021 Sep 28;144(13):1024-1038. doi: 10.1161/CIRCULATIONAHA.120.049755+.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...